z-logo
open-access-imgOpen Access
Identification of exacerbation risk in patients with liver dysfunction using machine learning algorithms
Author(s) -
Junfeng Peng,
Mei Zhou,
Chuan Chen,
Xiaohua Xie,
Ching Hsing Luo
Publication year - 2020
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0239266
Subject(s) - machine learning , exacerbation , artificial intelligence , algorithm , receiver operating characteristic , support vector machine , liver disease , medicine , cart , model for end stage liver disease , computer science , intensive care medicine , engineering , mechanical engineering , transplantation , liver transplantation
The prediction of the liver failure (LF) and its proper diagnosis would lead to a reduction in the complications of the disease and prevents the progress of the disease. To improve the treatment of LF patients and reduce the cost of treatment, we build a machine learning model to forecast whether a patient would deteriorate after admission to the hospital. First, a total of 348 LF patients were included from May 2011 to March 2018 retrospectively in this study. Then, 15 key clinical indicators are selected as the input of the machine learning algorithm. Finally, machine learning and the Model for End-Stage Liver Disease (MELD) are used to forecast the LF deterioration. The area under the receiver operating characteristic (AUC) of MELD, GLMs, CART, SVM and NNET with 10 fold-cross validation was 0.670, 0.554, 0.794, 0.853 and 0.912 respectively. Additionally, the accuracy of MELD, GLMs, CART, SVM and NNET was 0.669, 0.456, 0.794, 0.853 and 0.912. The predictive performance of the developed machine model execept the GLMs exceeds the classic MELD model. The machine learning method could support the physicians to trigger the initiation of timely treatment for the LD patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here